Vis enkel innførsel

dc.contributor.authorHalvorsen, Tarje Onsøien
dc.contributor.authorValan, Christine Damgaard
dc.contributor.authorJordhøy, Marit Slaaen
dc.contributor.authorGrønberg, Bjørn Henning
dc.date.accessioned2021-04-27T12:57:23Z
dc.date.available2021-04-27T12:57:23Z
dc.date.created2020-09-11T08:51:26Z
dc.date.issued2020
dc.identifier.citationJournal of Cachexia, Sarcopenia and Muscle. 2020, 11 (5), 1283-1290.en_US
dc.identifier.issn2190-5991
dc.identifier.urihttps://hdl.handle.net/11250/2739953
dc.description.abstractBackground: Standard treatment for patients with limited stage small cell lung cancer (LS SCLC) is concurrent platinum-etoposide chemotherapy and thoracic radiotherapy (TRT). Up to 30% of patients are cured, but severe toxicity is common, and we are not able to identify those who are cured or those who experience severe toxicity before chemoradiotherapy commences. Studies of other cancer patients show that low muscle mass and muscle radiodensity are associated with inferior survival and that a high drug dose per kilogram lean body mass (LBM) is associated with more toxicity, but this has not been investigated in LS SCLC. We analysed patients from a randomized trial comparing two schedules of TRT (n = 157) to investigate the prognostic and predictive role of these muscle measures in LS SCLC. Methods: Patients from a trial comparing once daily hypofractionated with twice daily hyperfractionated TRT were analysed. The skeletal muscle index (SMI), skeletal muscle radiodensity (SMD), and LBM were assessed from baseline computed tomography scans at the L3 level using the SliceOMatic software. Results: Images at the L3 level were available for 122 patients (77.7%). Median age was 64 years, 18% had performance status 2, and 38% had stage III. Grade 3-4 toxicity was observed in 89%, and 5% died from treatment-related side effects. Overall, the median overall survival was 23 months, and the 5 year survival was 25%. Median LBM was 45.2 (range: 16-65) kg, the median SMI 44.8 (range: 29-77) cm2 /m2 , and the median SMD 39.3 (range 16-62) HU. There were no significant associations between survival and any of the muscle measures in the univariable analyses (SMI: P = 0.906, SMD: P = 0.829) or in multivariable analyses adjusting for baseline characteristics (SMI: P = 0.836, SMD: P = 0.260). A higher cisplatin dose per kilogram LBM in the first course significantly increased the risk of grade 3-4 haematological toxicity (P = 0.011) and neutropenic infections (P = 0.012). Conclusions: Patients who received a high dose of cisplatin per kilogram LBM had more haematological toxicity and neutropenic infections than other patients. None of the muscle measures were independent prognostic factors for survival in our cohort of LS SCLC patients who underwent standard chemoradiotherapy. Keywords: Predictive factor; Prognostic factor; Skeletal muscle index; Skeletal muscle radiodensity; Survival. © 2020 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.en_US
dc.description.sponsorshipThe study was supported by the Central Norway Regional Health Authority (RHA), the Norwegian University of Science and Technology (NTNU), and the Norwegian Cancer Society.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.subjectPredictive factoren_US
dc.subjectPrognostic factoren_US
dc.subjectSkeletal muscle indexen_US
dc.subjectSkeletal muscle radiodensityen_US
dc.subjectSurvivalen_US
dc.titleAssociations between muscle measures, survival and toxicity in patients with limited disease small cell lung cancer receiving concurrent chemoradiotherapyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2020 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.en_US
dc.source.pagenumber1283-1290en_US
dc.source.volume11en_US
dc.source.journalJournal of Cachexia, Sarcopenia and Muscleen_US
dc.source.issue5en_US
dc.identifier.doi10.1002/jcsm.12583
dc.identifier.cristin1828922
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal